|
Real-time Estimate
Cboe BZX
14:02:17 2026-10-07 EDT
|
5-day change | 1st Jan Change | ||
| 2.485 USD | +0.61% |
|
-6.77% | +15.89% |
| 09-08 | Veru Advances Oral Sabizabulin into Planned Phase 2 Clinical Trial for Daraxonrasib Resistant Metastatic Pancreatic Cancer | CI |
| 08-10 | Veru Inc., Q3 2026 Earnings Call, Aug 10, 2026 |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VERU | Delayed | |
CBOE
| VERU | Real-time |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Neutral |
| Resistance | 2.8 | 4.23 | 3.4 |
| Spread/Res. | -11.43% | -41.37% | -27.06% |
| Spread/Supp. | +6.90% | +18.66% | +18.66% |
| Support | 2.32 | 2.09 | 2.09 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- VERU Stock
- Charts Veru Inc.
Select your edition
All financial news and data tailored to specific country editions
